摘要
目的评价奈达铂(NDP)或顺铂(DDP)联合多西他赛(TXT)治疗晚期非小细胞肺癌的疗效和不良反应。方法 96例初治的晚期非小细胞肺癌随机分为2组,试验组患者采用奈达铂加多西他赛(TN组),TXT 75mg/m2、d1;NDP 80mg/m2,分3d静脉注射,21d为1个周期。对照组患者采用顺铂加多西他赛(TP组),TXT 75mg/m2,DDP 80mg/m2,分3d静滴,21d为1个周期。结果 TN组中,CR 1例,PR 21例,有效率(CR+PR)为45.8%。TP组中,CR 2例,PR 19例,有效率为43.8%,两组间差异无统计学意义(P>0.05)。试验组白细胞与血小板减少与对照组比较,差异无统计学意义(P>0.05)。试验组消化道反应明显小于对照组(P<0.05)。结论奈达铂联合化疗治疗晚期非小细胞肺癌的疗效与顺铂相似,消化道反应小于顺铂组。奈达铂联合多西他赛化疗治疗晚期非小细胞肺癌有效,不良反应轻。
Objective To evaluate the efficacy and toxicity of combined chemotherapy of Nedaplatin（NDP） and Cisplatin（DDP） plus Docetaxel（TXT） for the patients with advanced non-small cell lung carcinoma.Methods A tolal of 96 previously untreated patients with advanced non-small cell lung carcinoma were divided into two groups.The patients in the experimental group were treated with NDP plus TXT,TXT were given 75 mg / m2 intraviously on days 1,and NDP 80 mg / m2 on days 1 to 3 of a 21-day cycle.While those in the control group received DDP plus TXT,TXT were given 75 mg / m2 intraviously on days 1,and DDP 80 mg / m2 on days 1 to 3 of a 21-day cycle.Results Efficacy：1 case achieved complete response（CR） in the experimental group,and 21 cases partial response（PR）.In comparison,2 cases achieved complete response in the control group,and 19 cases partial response（PR）.The response rate（CR ＋ PR） was45.8% and 43.8% in the two groups respectively without significant difference（P 〉 0.05）.Toxicity：The incidence of leukopenia and thrombocytopenia was not statistically different between the experimental group and the control group（P 〉 0.05）;however the nausea and vomiting response rate was much lower in the research group（P 〈 0.05）.Conclusion Although the efficacy rate of combined chemotherapy with NDP is similar with DDP,but the gastrointestinal reactions was lighter.The regimen NDP and TXT have shown activity in patients with advanced non-small cell lung carcinoma,and the toxicity is mild.
出处
《中国肿瘤临床与康复》
2014年第11期1337-1339,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
肺肿瘤
药物疗法
奈达铂
顺铂
多西他赛
Lung neoplasms
Drug therapy
Nedaplatin
Cisplatin
Docetaxel
